CANFNYSEPharmaceutical PreparationsUS GAAP · USD

Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. is a clinical-stage biotechnology company developing orally administered small-molecule therapeutics based on its A3 adenosine receptor platform. Its pipeline is focused on oncology, liver disease, and inflammatory diseases, with development and partnering activities centered in Israel and commercial/regulatory interactions in the United States and Europe.

Kysy yhtiöstä
Liikevaihto0,4milj. USD
−39,9 %v/v
Liikevoitto (EBIT)−10,0milj. USD
−22,4 %v/v
EBIT-marginaali−2 456,8%
−1 250,6 %-yks.v/v
Nettotulos−9,8milj. USD
−24,7 %v/v
Vapaa kassavirta−9,0milj. USD
−17,1 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−15−10−505milj. USD2020: 0,76 milj. USD2020: EBIT −14 milj. USD20202021: 0,85 milj. USD2021: EBIT −13 milj. USD20212022: 0,81 milj. USD2022: EBIT −10 milj. USD20222023: 0,74 milj. USD2023: EBIT −8,2 milj. USD20232024: 0,67 milj. USD2024: EBIT −8,1 milj. USD20242025: 0,41 milj. USD2025: EBIT −10,0 milj. USD20250,41−10,0
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
Oncology drug candidates40 %

Clinical-stage therapies for cancer indications, including hepatocellular carcinoma and pancreatic cancer.

Inflammatory disease drug candidates30 %

Clinical-stage therapies for autoimmune and inflammatory conditions such as psoriasis.

Liver disease drug candidates20 %

Clinical-stage therapies targeting liver-related diseases including MASH and cirrhosis.

Licensing and partnering agreements10 %

Out-licensing and collaboration agreements that monetize pipeline rights through upfront and milestone payments.

Asiakkaat

Can-Fite sells into a business-to-business pharmaceutical ecosystem rather than directly to patients. Its counterparties are mainly large pharmaceutical companies, biotechnology firms, and potential strategic partners that license drug candidates, fund development, or commercialize assets in specific territories. Ultimately, the therapeutic end users are physicians and patients in oncology, hepatology, and inflammatory disease markets.

Pharmaceutical licensing partners

Large pharma groups that license Namodenoson or Piclidenoson for selected regions or indications to expand pipelines.

Biotechnology collaboration partners

Biotech firms that partner on development, shared trials, or co-commercialization of clinical assets.

Commercialization partners

Companies that take rights in defined territories and handle market access and launch execution.

Clinical trial sites and investigators

Hospitals and research centers running the company's Phase II and Phase III studies.

Patients and treating physicians

Patients with HCC, psoriasis, MASH, pancreatic cancer, or rare disease indications who benefit from the therapies being tested.

Strategia

Can-Fite’s strategy is to advance a small number of clinical-stage assets through late-stage trials while using partnering and licensing to broaden development reach. The company is also positioning its A3AR platform as a repeatable source of orally administered therapies across oncology, liver disease, and inflammatory disease. Regulatory designations and regional licensing agreements are important because they can reduce development friction and create optionality for future commercialization.

Late-stage clinical advancementLyhyt aikaväli

Phase III data are the main value driver for a clinical-stage biotech and determine partnering leverage.

Partnering and licensingLyhyt aikaväli

Out-licensing can provide non-dilutive capital and territory-specific commercialization capacity.

Regulatory pathway executionKeskipitkä aikaväli

FDA and EMA alignment can improve the path to approval and market access for lead assets.

Platform expansionKeskipitkä aikaväli

A3AR biology may support additional indications and increase the value of the pipeline.

Maantiede

The company is incorporated in Israel and has principal executive offices in Ramat Gan, while its securities trade in the United States on NYSE American and in Israel on TASE. Its development programs are designed for regulatory pathways in the United States and Europe, and partnering activity also includes international licensing arrangements. Clinical and conference-related business activity is visible in the United States, particularly through U.S. regulatory engagement and industry events.

Riskit

The company depends on successful clinical development of a small number of lead assets, so trial setbacks or weak efficacy data would materially affect valuation. As a biotech with no broad commercial product base, it also faces financing, regulatory, and partnering execution risk, while the biology of oncology and inflammatory disease drug development carries high attrition rates. Any delay in approvals, licensing, or market access would slow the path from pipeline to revenue.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Late-stage clinical failure1Regulatory approval risk3Financing and dilution risk2Partnering and licensing execution risk4
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Late-stage clinical failureVaikutus: KriittinenTodennäköisyys: Kohtalainen

    Phase III programs are the main value drivers and negative data can sharply reduce future licensing and approval prospects.

    Kohdistuu: Namodenoson and Piclidenoson

  2. Financing and dilution riskVaikutus: KorkeaTodennäköisyys: Korkea

    Clinical-stage development is capital intensive and the company may need external funding before commercialization.

    Kohdistuu: Development funding

  3. Regulatory approval riskVaikutus: KorkeaTodennäköisyys: Kohtalainen

    FDA and EMA approval depends on meeting predefined efficacy and safety endpoints and may be delayed or denied.

    Kohdistuu: U.S. and Europe

  4. Partnering and licensing execution riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Future monetization depends on finding partners willing to pay upfronts, milestones, and royalties.

    Kohdistuu: Global out-licensing

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition for licensing deals

Upfront and milestone payments from regional agreements must be recognized based on performance obligations and contract terms.

Vaikutus: Affects reported revenue timing and volatility

Clinical trial accruals

Trial costs are estimated from patient enrollment, site activity, and vendor progress before invoices arrive.

Vaikutus: Affects R&D expense and liabilities

Warrants and equity-linked instruments

Private placements can include warrants that require valuation and remeasurement judgments.

Vaikutus: Affects financing-related gains/losses and balance sheet presentation

Share-based compensation

Employee and director awards are common in biotech and create non-cash expense using valuation assumptions.

Vaikutus: Affects operating expense and diluted share count

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Galmed Pharmaceuticals Ltd.

EOCN · Pharmaceutical Preparations

Candel Therapeutics, Inc.

CADL · Biological Products, (No Diagnostic Substances)

BioLineRx Ltd.

BLRX · Pharmaceutical Preparations

Arbutus Biopharma Corp

ABUS · Pharmaceutical Preparations

Aptose Biosciences Inc.

APTOF · Biological Products, (No Diagnostic Substances)

Arrowhead Pharmaceuticals, Inc

ARWR · Pharmaceutical Preparations

Päivitetty: 28.9.2026

Can-Fite BioPharma Ltd. (CANF) liikevaihto, tulos ja tunnusluvut 2025 – Clarifo